Life Science: SMSF Trustees should know about these emerging AUS & NZ companies that are changing the biotech landscape
The success of life science companies CSL, Resmed and Cochlear are well known and they are now worth over $130 billion in total, but they were once small
PPM’s Core Strategy, and one which is particularly important for the trustees of Self Managed Super Funds as it focuses on well established companies with strong financial positions with attractive returns. However, in addition to our Core Investment Strategy, we also do invest in earlier stage companies. While these don’t have the level of predictability of the Core Strategy, and they are not for every SMSF trustee, we feel it is important to support these companies as from their midst will emerge future leaders and they provide diversified investment opportunities.
Content provided by:
For more information please visit the Private Portfolio Managers site